CYP2C19 polymorphisms and lipoproteins associated with clopidogrel resistance in children with Kawasaki disease in China: A prospective study

Mingming Zhang, Meng Li, Yeshi Chen, Xiaohui Li, Lin ShiFrontiers in Cardiovascular Medicine 2022 · DOI

This study identifies a critical link between genetics and metabolism in pediatric cardiology, revealing that nearly one-third of children with Kawasaki disease (KD) may not respond effectively to clopidogrel. By combining CYP2C19 genetic testing with lipid profile analysis (HDL and LDL), researchers have developed a predictive model that could help pediatricians move toward personalized antiplatelet therapy.

What Problem Does This Paper Address?

Kawasaki disease is an acute vasculitis (inflammation of blood vessels) that primarily affects children under five. Its most dangerous complication is coronary artery thrombosis (CAT), which can lead to heart attacks or sudden death. To prevent this, doctors use antiplatelet drugs like aspirin and clopidogrel.

However, clopidogrel is a prodrug—it is inactive when swallowed and must be converted into its active form by the liver enzyme CYP2C19. If a patient has genetic variants that result in "Loss-of-Function" (LOF) of this enzyme, the drug won't work effectively, a phenomenon known as clopidogrel resistance (CR). While well-studied in adults with heart disease, the prevalence and risk factors for CR in children with Kawasaki disease remained a significant knowledge gap, particularly in East Asian populations where LOF alleles are more common.

Methods

The researchers conducted a prospective, single-center study in Beijing, China, involving 346 children with KD. Their approach combined three distinct layers of data:

  1. Genotyping: They used the MassARRAY platform to identify specific CYP2C19 alleles (2, 3, and *17). Patients were categorized by their metabolic phenotype (e.g., Normal, Intermediate, or Poor metabolizers).
  2. Platelet Function Testing: Using Light Transmission Aggregometry (LTA)—the "gold standard" for measuring how well platelets clump together—they measured the response to clopidogrel. CR was defined as a platelet aggregation rate of $\ge$ 50% despite treatment.
  3. Clinical/Laboratory Indicators: They tracked a wide range of markers, including liver and renal function, and specifically focused on lipoproteins (HDL, LDL, and triglycerides).

The team then used multivariable logistic regression to determine which factors independently predicted drug resistance.

Datasets

The study utilized a primary clinical dataset of 346 children diagnosed with KD between 2019 and 2021.

  • Genetic Cohort: All 346 were genotyped to establish a baseline distribution of CYP2C19 variants.
  • Efficacy Cohort: 118 children who received clopidogrel and completed platelet testing were used to analyze the impact of genetics on drug resistance.
  • Multivariable Cohort: 114 children had complete laboratory data for the final predictive model.

Key Insights and Ideas

  • High Genetic Risk in East Asians: A staggering 56.9% of the children carried at least one LOF allele. This is significantly higher than the ~30% typically seen in Caucasian or African American populations, highlighting the need for region-specific clinical guidelines.
  • The Lipid Connection: Beyond genetics, the study found that lipoproteins play a major role. High LDL (the "bad" cholesterol) was a risk factor for resistance, while high HDL (the "good" cholesterol) acted as a protective factor.
  • Biological Synergy: The authors suggest that LDL may promote platelet activation directly, while HDL inhibits it. When a patient has both a genetic "slow-start" for the drug (CYP2C19 LOF) and a pro-thrombotic lipid environment (high LDL), the drug is significantly more likely to fail.
  • Moving Beyond Genotype: The study found that genotype alone doesn't tell the whole story; some "normal" metabolizers still showed resistance, suggesting that clinical factors like lipid levels are essential for an accurate prediction.

Key Results

  • CR Prevalence: 31.4% of the children met the criteria for clopidogrel resistance.
  • Independent Risk Factors:
    • CYP2C19 LOF allele: Increased risk of resistance by nearly 4x (OR 3.922).
  • High LDL: Every unit increase in LDL raised the risk (OR 1.675).
  • Low HDL: Higher HDL was strongly protective (OR 0.120).
  • Predictive Power: The combined model (Genetics + HDL + LDL) achieved an AUC of 0.769, with a sensitivity of 70.3% and specificity of 74.0%.
  • Thresholds: The researchers identified specific cut-off values for risk: HDL $\le$ 0.70 mmol/L and LDL $\ge$ 2.92 mmol/L.

Limitations and Future Work

The authors acknowledge several limitations:

  1. Single-Center Study: The cohort was exclusively Chinese, meaning the specific lipid cut-offs and genetic frequencies might not apply to other ethnic groups.
  2. Missing Genetic Links: Other genes involved in drug absorption (like ABCB1) were not tested.
  3. Clinical Outcomes: The study used a laboratory definition of resistance (platelet aggregation) rather than long-term clinical outcomes like the actual rate of heart attacks or blood clots.

Future Work: The team calls for multi-center studies with larger, more diverse populations and long-term follow-up to see if adjusting therapy based on these markers actually reduces the incidence of coronary artery complications in KD patients.

Summary updated

Abstract

Carrying CYP2C19 LOF allele, low levels of high-density lipoprotein, and high levels of low-density lipoprotein were independent risk factors for CR in children with KD in China. This may benefit pediatricians in choosing appropriate individualized antiplatelet therapy.
BibTeX
@inproceedings{zhang2022cyp,
  author = {Mingming Zhang and Meng Li and Yeshi Chen and Xiaohui Li and Lin Shi},
  title = {{CYP2C19 polymorphisms and lipoproteins associated with clopidogrel resistance in children with Kawasaki disease in China: A prospective study}},
  booktitle = {Frontiers in Cardiovascular Medicine},
  year = {2022},
  doi = {10.3389/fcvm.2022.925518},
}
Figure